Camallergy Ltd has been awarded 1.1M in funding for novel peanut allergy treatment
- 10 March 2021
- News
Camallergy (Cambridge Allergy Ltd) a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, has announced it’s been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.
It is hoped that the funding will accelerate the development of the peanut allergy immunotherapy for planned phase 3 trials.
For more information, visit the Camallergy website – www.camallergy.com/
